Mentor: Dr. Alexandra Lucas
College of Medicine
"I applied to the Scholars program to further enhance my research experience by learning more about research techniques, data analysis and the presentation of results. In particular, I hope to learn more about how the adverse effects of liver ischemia and reperfusion can be reduced in certain mouse models. The results of this project can help perform more successful organ transplants."
Microbiology and Cell Science, Psychology
- Pre-Med Track, Medical School
- Pathology of liver ischemia (reducing effects with viral proteins)
- Shand's Oncology Unit - Footprints Buddy and Support System
- Shand's Internal Medicine Unit
- International Medical Outreach medical service trip
- TopSoccer Organization
Hobbies and Interests
- Hanging out with friends and family
- Watching movies
Analysis of anti-inflammatory proteins in inhibition of Vasculopathy in Liver Ischemia/Reperfusion Injury mouse models
Liver Ischemia and Reperfusion Injury, an innate immunity-dominated inflammatory event, remains a critical problem in clinical organ transplantation. In the specific case of the liver, IRI causes about 10% of early graft failure and can lead to a higher incidence of acute and chronic rejection. Hepatic IR damage which can occur in multiple situations such as liver transplantation, trauma, hemorrhage shock or liver surgery, is a serious clinical complication that leads to impaired liver function due to extensive hepatocellular loss. The mechanisms responsible for hepatic injury are not well understood but some studies show that T lymphocytes are key mediators in IR-triggered liver inflammation. This research project is aimed at reducing the adverse effects of IR injury through the administration of the viral proteins, Serp 1, NSP and M-T7 on mice with IRI. This can ultimately lead to more successful liver transplants and decreased graft failures. Blood supply to the mice’s left/middle lobes will be blocked by clamping the portal vein and hepatic artery for 90 minutes. The clamp is then removed, initiating reperfusion and at a follow-up of 24 hours, the liver will be harvested. The protein will be administered 30 minutes before ischemia and 9 days after reperfusion by infusion into the tail vein. Immunostaining, Hematoxylin and Eosin staining other forms of staining will be used to examine the effects of the viral proteins on inflammation and hepatocellular loss. The results of this project can be directly applied to real world liver transplant patients. Finding the correct protein can help reduce the number of liver transplant failures. The inflammation and liver damage can be minimized in these patients with the results of this experiment.